Difference between revisions of "Daratumumab and hyaluronidase (Darzalex Faspro)"
Jump to navigation
Jump to search
(added package insert, links) |
m |
||
| Line 6: | Line 6: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Light chain (AL) amyloidosis]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
| Line 12: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *5/1/2020: [https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma | + | ===[[Light chain (AL) amyloidosis]]=== |
| − | + | *1/15/2021: Accelerated approval in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed [[light chain (AL) amyloidosis]]. ''(New disease entity)'' | |
| − | * | + | ===[[Multiple myeloma]] |
| − | * | + | *5/1/2020: [https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma Approved] for adult patients with newly diagnosed or relapsed/refractory [[multiple myeloma]] in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. |
| − | * | + | *5/1/2020: Approved for adult patients with newly diagnosed or relapsed/refractory [[multiple myeloma]] in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, |
| + | *5/1/2020: Approved for adult patients with newly diagnosed or relapsed/refractory [[multiple myeloma]] in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, | ||
| + | *5/1/2020: Approved for adult patients with newly diagnosed or relapsed/refractory [[multiple myeloma]] as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. | ||
==Also known as== | ==Also known as== | ||
| Line 30: | Line 33: | ||
[[Category:Anti-CD38 antibodies]] | [[Category:Anti-CD38 antibodies]] | ||
| + | [[Category:Light chain (AL) amyloidosis medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
Revision as of 01:08, 16 January 2021
General information
Class/mechanism: Anti-CD38 antibody, human monoclonal IgG1 kappa. Daratumumab binds to CD38 and causes apoptosis in CD38-expressing cells via Fc mediated cross-linking, complement-dependent cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP). CD38 is present on the cell surface of multiple myeloma (MM), plasma leukemia, and natural killer (NK) cells.[1][2][3]
Route: SC
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
Light chain (AL) amyloidosis
- 1/15/2021: Accelerated approval in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed light chain (AL) amyloidosis. (New disease entity)
- 5/1/2020: Approved for adult patients with newly diagnosed or relapsed/refractory multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant.
- 5/1/2020: Approved for adult patients with newly diagnosed or relapsed/refractory multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy,
- 5/1/2020: Approved for adult patients with newly diagnosed or relapsed/refractory multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy,
- 5/1/2020: Approved for adult patients with newly diagnosed or relapsed/refractory multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
Also known as
- Generic name: daratumumab and hyaluronidase-fihj
- Brand name: Darzalex Faspro